The authors conclude that their study lends mechanistic support that mangafodipir and calmangafodipir exert the neuroprotective effects through their manganese superoxide dismutase (MnSOD)-mimetic and iron chelating activities, in relation to oxaliplatin-associated chemotherapy-induced peripheral neuropathy (CIPN). This evidence concerns the gene SOD2 and peripheral neuropathy.